Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH2616 in Advanced Solid Tumors
NCT07260513Phase 1Active, not recruiting
- Sponsor
- Genhouse Bio
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GH2616 in solid tumor (advanced stage), sponsored by Genhouse Bio. Primary endpoints: Incidence and severity of adverse events and serious adverse events at 2 years, Dose Limited Toxicity at 21 days and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
GH2616
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07260513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260513.